Csenge Advisory Group Invests $843,000 in Stryker Corporation $SYK

Csenge Advisory Group acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, HoldingsChannel reports. The fund acquired 2,677 shares of the medical technology company’s stock, valued at approximately $843,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Varma Mutual Pension Insurance Co increased its stake in shares of Stryker by 10.5% in the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after purchasing an additional 5,100 shares during the period. QRG Capital Management Inc. boosted its stake in Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after purchasing an additional 4,186 shares during the period. Swedbank AB boosted its stake in Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after purchasing an additional 7,934 shares during the period. Crossmark Global Holdings Inc. grew its holdings in Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after buying an additional 6,367 shares during the last quarter. Finally, Royal Bank of Canada increased its position in Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after buying an additional 199,863 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

SYK opened at $340.20 on Thursday. The stock’s 50 day simple moving average is $326.19 and its 200-day simple moving average is $332.95. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock has a market cap of $130.49 billion, a PE ratio of 35.25, a P/E/G ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the business earned $3.13 earnings per share. Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Analyst Ratings Changes

SYK has been the subject of a number of research analyst reports. Argus set a $370.00 price target on Stryker in a report on Thursday, July 9th. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Canaccord Genuity Group cut their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. JPMorgan Chase & Co. reduced their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Activity

In related news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 315,370 shares of company stock worth $98,463,501. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.